GERON CORP (GERN) Debt / Equity
- 2024-09-30: Debt/Equity Ratio 0.29.
- 2024-06-30: Debt/Equity Ratio 0.27.
- 2024-03-31: Debt/Equity Ratio 0.24.
- 2023-12-31: Debt/Equity Ratio 0.33.
Complete source-backed debt/equity ratio history.
- Available history
- 2022-06-30 to 2024-09-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|
| 2024-09-30 | 0.29 |
|---|
| 2024-06-30 | 0.27 |
|---|
| 2024-03-31 | 0.24 |
|---|
| 2023-12-31 | 0.33 |
|---|
| 2023-09-30 | 0.18 |
|---|
| 2023-06-30 | 0.17 |
|---|
| 2023-03-31 | 0.16 |
|---|
| 2022-12-31 | 0.64 |
|---|
| 2022-09-30 | 0.47 |
|---|
| 2022-06-30 | 0.35 |
|---|
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|
| 2023-12-31 | 0.33 |
|---|
| 2022-12-31 | 0.64 |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
|---|
| Wave Life Sciences, Inc. (WVE) | | $0.780B | -5.56 |
|---|
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
|---|
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
|---|